Using metabolomics to predict treatment response in rectal cancer
Official title: Metabolomic Profiles as Predictors of Treatment Response and Toxicities in Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy
Run by Chang Gung Memorial Hospital · NCT06831669 · Data updated 2026-11-12
This study is testing whether certain substances in the body can help predict how well patients with advanced rectal cancer will respond to a specific treatment plan and if they might face any side effects.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Guishan, Taoyuan) |
| Status | Recruiting |
| Started | January 5, 2024 |
| Main results expected | December 12, 2028 |
| Study ends | December 12, 2033 |
| Registry record updated | April 15, 2026 |
| Trial ID | NCT06831669 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals with histologically confirmed adenocarcinoma of the rectum who are scheduled to receive total neoadjuvant therapy.
✕Probably not a fit
Patients who have previously undergone pelvic radiation therapy or have inflammatory bowel disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the metabolomic profiles of patients with locally advanced rectal cancer who are scheduled to receive total neoadjuvant therapy (TNT). By collecting blood, urine, tissue, and fecal samples at various stages of treatment, the study seeks to identify specific metabolites that can predict how well patients will respond to TNT and the likelihood of experiencing treatment-related toxicities, such as radiation proctitis. The goal is to enhance precision health by selecting patients who are most likely to benefit from TNT while minimizing complications.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment plans that improve outcomes and reduce side effects for rectal cancer patients.
How similar studies have gone: There is a growing body of evidence suggesting that metabolomics can effectively predict treatment response and toxicity in cancer patients, although most prior studies have focused on long-course chemoradiotherapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the rectum * Scheduled to receive total neoadjuvant therapy Exclusion Criteria: * Previous pelvic radiation therapy * Inflammatory bowel disease
Where it's running
-
Linkou Chang Gung Memorial Hospital
Guishan, Taoyuan, Taiwan Recruiting
Study contacts
- Study coordinator: Eric Yi-Liang Shen, PhD
- Email: pts@cgmh.org.tw
- Phone: 0975366392
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Posterior tibial nerve stimulation to help bowel function after rectal cancer surgery
This trial tests whether posterior tibial nerve stimulation can improve fecal continence and quality of life for adults who had rectal cancer surgery.
-
Comparing two surgical approaches for low rectal cancer treatment
This study is testing whether a combination of two surgical methods for low rectal cancer works better than just one after patients have received chemotherapy and radiation.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Heart rate variability biofeedback, mindfulness, or psychoeducation after knee replacement
This trial tests whether heart rate variability biofeedback, mindfulness, or psychoeducation help people recover better after total knee arthroplasty.
-
Intelligent Sexual Health Help System for Gynecologic Cancer Patients
A smartphone-based sexual health education and consultation system called LillyBot will be tested with gynecologic cancer patients to see if it improves sexual well-being.
-
Hyperpolarized 13C-MMRI and Metabolomics in Rectal Cancer
This study tests whether a special MRI method and metabolic analysis can better predict how rectal cancer responds to chemoradiotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.